The ADD1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HEK293T human embryonic kidney epithelial cell line. This heterogeneous pool of cells carries targeted disruptions in ADD1, encoding alpha-adducin, and serves as a loss-of-function model for studying actin-spectrin network assembly, cell adhesion, and intracellular signaling. The polyclonal format preserves cellular diversity for robust functional analyses of ADD1-dependent processes.
The HEK293T host cell line, a highly transfectable derivative of HEK293, constitutively expresses SV40 large T antigen, enabling episomal plasmid replication and elevated protein expression. HEK293T cells retain epithelial morphology and key junctional proteins, making them suitable for adherens and tight junction studies. Their embryonic kidney origin provides a physiologically relevant model for ion transport, cytoskeletal organization, and signaling pathway analyses that intersect with alpha-adducin function.
Alpha-adducin, encoded by ADD1, is a cytoskeletal protein that caps the barbed ends of actin filaments and recruits spectrin, thereby stabilizing the cortical cytoskeleton and regulating cell adhesion. Its function is modulated by PKC and PKA-mediated phosphorylation, calcium/calmodulin binding, and Rho GTPase signaling. It directly binds spectrin, actin, beta- and gamma-adducin, and calmodulin, and participates in E-cadherin?Cbased adhesion complexes while influencing Na+/K+ ATPase localization. Alpha-adducin operates at the convergence of adherens junction, tight junction, actin cytoskeleton, Wnt, and Hippo pathways.
CRISPR/Cas9-mediated disruption of ADD1 in HEK293T cells impairs spectrin-actin network formation, potentially compromising adherens junction integrity and ion transporter anchoring. This polyclonal knockout model facilitates investigation of epithelial cell adhesion, membrane stability, and cytoskeletal dynamics in the absence of alpha-adducin. The well-characterized HEK293T signaling environment provides a tractable system to dissect molecular consequences of ADD1 loss on morphology, migration, and mechanotransduction, with relevance to hypertension and cancer metastasis.
Researchers can utilize these cells for protein expression analysis via Western blotting, mRNA quantification by RT-qPCR, cytoskeletal visualization by immunofluorescence, and interaction studies via co-immunoprecipitation of spectrin-adducin complexes. Functional assays include cell adhesion, wound healing migration, Rho GTPase activation, and calcium flux measurements. This knockout population supports drug screening targeting cytoskeletal pathways and modeling of salt-sensitive hypertension and cardiovascular disease. For further information, contact Ascent Research.
